Lexeo Therapeutics Inc. C... (LXEO)
4.50
0.41 (10.02%)
At close: Mar 25, 2025, 3:59 PM
4.31
-4.22%
Pre-market: Mar 26, 2025, 07:19 AM EDT
10.02% (1D)
| Bid | 4.31 |
| Market Cap | 148.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -86.6M |
| EPS (ttm) | -3.09 |
| PE Ratio (ttm) | -1.46 |
| Forward PE | -1.89 |
| Analyst | Buy |
| Ask | 4.44 |
| Volume | 2,167,303 |
| Avg. Volume (20D) | 454,615 |
| Open | 4.19 |
| Previous Close | 4.09 |
| Day's Range | 3.72 - 4.56 |
| 52-Week Range | 2.32 - 19.50 |
| Beta | 3.88 |
About LXEO
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associat...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 3, 2023
Employees 72
Stock Exchange NASDAQ
Ticker Symbol LXEO
Website https://www.lexeotx.com
Analyst Forecast
According to 5 analyst ratings, the average rating for LXEO stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 411.11% from the latest price.
Stock Forecasts2 days ago
+50.92%
Lexeo Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
4 months ago
-0.65%
Lexeo Therapeutics shares are trading higher. Leerink Partners maintained an Outperform rating on the stock.
